We serve Chemical Name:6-Ethoxy-5-methoxy-1H-indene CAS:778638-75-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:6-Ethoxy-5-methoxy-1H-indene
CAS.NO:778638-75-8
Synonyms:6-Ethoxy-5-methoxy-1H-indene
Molecular Formula:C12H14O2
Molecular Weight:190.23800
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:18.46000
Exact Mass:190.09900
LogP:2.66320
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 6-Ethoxy-5-methoxy-1H-indene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Ethoxy-5-methoxy-1H-indene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Ethoxy-5-methoxy-1H-indene Use and application,6-Ethoxy-5-methoxy-1H-indene technical grade,usp/ep/jp grade.
Related News: (For more on Stevanato, see The Covid Vaccine Will Require Billions Of Tiny Glass Vials—And This Italian Billionaire Family Is Making Them.) (R)-7-Bromo-2,3,4,5-tetrahydro-4-(ethenylsulfonyl)-3-(phenylmethyl)-1H-1,4-benzodiazepine manufacturers Soliris, first approved for generalized myasthenia gravis (gMG) in 2017, carries a list price of about $470,000 annually. But to ICER, that cost is “well beyond typical thresholds.” 6,8-dichloro-5-methoxy-2-methylquinoxaline suppliers For its part, the FDA’s representative at the meeting, Doran Fink, M.D., said the drug regulator is “working as rapidly as possible to conduct a thorough and comprehensive” review of all the COVID-19 vaccines that have applied for full approval. Pfizer and Moderna recently submitted their applications for a full nod. 2-Bisphenylcarbinol-3-oxa-5α-cholestan vendor & factory The results provided a formulation amenable to two dosage strengths by applying a proportional dosing weight method.” The product is currently in late-stage development with the New Drug Application filing expected in late 2021.,For example, by using molecular modeling tools to achieve rapid de novo design of new enzymes, it may be possible to increase activity, enhance temperature stability, or improve solvent compatibility to better align with the process in question.
